Funded Biotechnology Startups in Montréal
Across the 19 most recent biotechnology funding entries in Montréal, Congruence Therapeutics’ $40M round on 2026-03-19 is the largest disclosed amount, and…
Across the 19 most recent biotechnology funding entries in Montréal, Congruence Therapeutics’ $40M round on 2026-03-19 is the largest disclosed amount, and it sits just above Nomic’s $42M (2024-09-17) as one of the top-disclosed outliers, while most other disclosed rounds are clustered between $1M and $13M (for example, Betterlife Pharma’s $1M on 2025-05-06 and Theratechnologies’ $13M on 2023-10-26). Stage disclosure is also uneven: “Series Unknown” appears in 8 of 19 rows, and “undisclosed” amounts show up in 3 rows (Cura Therapeutics on 2025-05-06; MY01 on 2024-08-21; AAVAA on 2023-05-04), limiting how consistently stage and size can be compared.
Dates span from 2021-05-21 (Giiant Pharma) to 2026-03-19 (Congruence Therapeutics). Within that window, activity is concentrated in the later years, with multiple rounds in 2024–2025 (e.g., Nomic’s $42M on 2024-09-17; Morphocell Technologies’ $10M on 2025-12-01), and the geographic pattern stays consistently Montreal/Montreal, Quebec, Canada with no competing city names in the rows shown.
Most recent rounds
19 shownRelated listings
Frequently asked
What are the biggest disclosed rounds here, and how do they compare to the typical disclosed deal size?
The largest disclosed amount is Nomic at $42M on 2024-09-17, with Congruence Therapeutics also near the top at $40M on 2026-03-19. Outside those two, most disclosed rounds shown fall well below $13M (e.g., Theratechnologies at $13M on 2023-10-26 and Ananda Devices at $260K on 2024-08-16), making the $40M–$42M pair clear size outliers.
Is there a tight time cluster in the most recent years of this Montréal biotechnology list?
Yes, the listing is heaviest in 2024–2025, with several sizable events including Nomic’s $42M on 2024-09-17, NeuroTracker’s $2M on 2024-10-31, Synucure Therapeutics’ $3M on 2025-04-07, and Morphocell Technologies’ $10M on 2025-12-01. The range spans 2021-05-21 to 2026-03-19, but the density increases closer to the present.
How often is stage ambiguous, and does that affect interpretation of deal size versus stage?
Stage is listed as “Series Unknown” in 8 of 19 rows, and “undisclosed” amounts appear in 3 rows (Cura Therapeutics on 2025-05-06; MY01 on 2024-08-21; AAVAA on 2023-05-04). This means a large share of entries cannot be cleanly compared by disclosed stage and size simultaneously.
Are there any notable outliers besides the top-end $40M+ rounds?
The other strong outlier on the downside is Ananda Devices at $260K on 2024-08-16, which is far below most other disclosed amounts in the table (many sit at $500K+ or multiple millions). On the other end, Inversago Pharma’s $69M on 2022-10-17 is a distinct high-disclosed event relative to the rest of the disclosed range.
Does the geography vary within the Montréal biotechnology category shown?
Geography is effectively consistent across the rows: all entries are in Montréal/Montreal, Quebec, Canada (for example, Congruence Therapeutics in Montréal with $40M on 2026-03-19 and Sensoreal in Montreal with $230K on 2022-07-11). No alternate city names appear within the 19 rows shown.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.